Elevance Health (ELV) EBIT (2009 - 2026)

Elevance Health (ELV) has 18 years of EBIT data on file, last reported at $765.0 million in Q1 2026.

• Quarterly EBIT rose 29.66% year-over-year to $765.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.4 billion (up 8.87% YoY) and the FY2025 annual result came in at $2.2 billion, up 6.97% from the prior year.
• EBIT rose to $765.0 million in Q1 2026 per ELV's latest filing, from $493.0 million in the prior quarter.
• Across five years, EBIT topped out at $765.0 million in Q1 2026 and bottomed at $360.0 million in Q1 2022.
• The 5-year median for EBIT is $493.0 million (2023), against an average of $489.4 million.
• The widest annual swing landed in 2023, when EBIT surged 41.82%; it then retreated 6.45% in 2025.
• Tracing ELV's EBIT over 5 years: stood at $373.0 million in 2022, then surged by 41.82% to $529.0 million in 2023, then slipped by 0.38% to $527.0 million in 2024, then retreated by 6.45% to $493.0 million in 2025, then soared by 55.17% to $765.0 million in 2026.
• Per Business Quant, the three latest ELV EBIT figures stand at $765.0 million (Q1 2026), $493.0 million (Q4 2025), and $625.0 million (Q3 2025).

Peer Comparison